THEMISMED

Themis Medicare Share Price

₹160.12 -10.62 (-6.22%)

Stock Result Declared

21 May, 2025 04:19

SIP TrendupStart SIP in THEMISMED

Start SIP

Performance

  • Low
  • ₹158
  • High
  • ₹175
  • 52 Week Low
  • ₹115
  • 52 Week High
  • ₹317
  • Open Price₹172
  • Previous Close₹171
  • Volume239,973

Investment Returns

  • Over 1 Month + 19.17%
  • Over 3 Month -12.24%
  • Over 6 Month -44.05%
  • Over 1 Year -23.97%
SIP Lightning

Smart Investing Starts Here Start SIP with Themis Medicare for Steady Growth!

Invest Now

Themis Medicare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49.4
  • PEG Ratio
  • -1.6
  • Market Cap Cr
  • 1,474
  • P/B Ratio
  • 3.6
  • Average True Range
  • 9.89
  • EPS
  • 5.01
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -2.23
  • RSI
  • 62.86
  • MFI
  • 78.53

Themis Medicare Financials

Themis Medicare Technicals

EMA & SMA

Current Price
₹160.12
-10.62 (-6.22%)
pointer
  • stock-down_img
  • Bearish Moving Average 5
  • stock-up_img
  • Bullish Moving Average 11
  • 20 Day
  • ₹140.06
  • 50 Day
  • ₹150.06
  • 100 Day
  • ₹175.99
  • 200 Day
  • ₹200.21

Resistance and Support

164.3 Pivot Speed
  • R3 187.22
  • R2 180.97
  • R1 170.55
  • S1 153.88
  • S2 147.63
  • S3 137.21

What's your outlook on Themis Medicare?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Themis Medicare Ltd. develops and manufactures pharmaceutical products across segments like anti-infectives, pain management, and critical care. With 3 manufacturing facilities, it serves over 40 countries, offering innovative therapies for a wide range of medical needs.

Themis Medicare has an operating revenue of Rs. 431.63 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 9% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 20% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 14 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Themis Medicare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-20 Audited Results & Final Dividend
2025-02-14 Quarterly Results
2024-10-25 Quarterly Results
2024-07-26 Quarterly Results
2024-05-14 Audited Results & Final Dividend
Date Purpose Remarks
2023-10-10 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Themis Medicare F&O

Themis Medicare Shareholding Pattern

67.15%
0%
0.14%
0.01%
23.93%
8.77%

About Themis Medicare

  • NSE Symbol
  • THEMISMED
  • BSE Symbol
  • 530199
  • Managing Director & CEO
  • Dr. Sachin D Patel
  • ISIN
  • INE083B01024

Similar Stocks to Themis Medicare

Themis Medicare FAQs

Themis Medicare share price is ₹160 As on 21 May, 2025 | 04:05

The Market Cap of Themis Medicare is ₹1473.7 Cr As on 21 May, 2025 | 04:05

The P/E ratio of Themis Medicare is 49.4 As on 21 May, 2025 | 04:05

The PB ratio of Themis Medicare is 3.6 As on 21 May, 2025 | 04:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23